Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-621 in Advanced Solid Tumors and Hematologic Malignancies
NCT03082209Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2017
- Primary completion
- Jan 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
Phase 1, open-label trial of eftozanermin in solid tumor, hematologic malignancy, colorectal cancer (CRC) and 3 more, sponsored by AbbVie Inc. Primary endpoints: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) up to 21 days, Area under the serum/plasma concentration time curve up to 64 days and 4 more. Started Mar 2017; status: completed.
02
Drugs
eftozanermin
03
Conditions
solid tumorhematologic malignancycolorectal cancer (CRC)acute myeloid leukemia (AML)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03082209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03082209.